Study wrapper · #798
Exercise-induced anaphylaxis with a cofactor of GIP/GLP-1 receptor agonist: A case report.
Editor's note
This brief case report describes a patient who developed exercise-induced anaphylaxis after starting the dual GIP/GLP-1 receptor agonist tirzepatide, with resolution of the reactions after tirzepatide was discontinued. The 'dechallenge', symptoms improving on stopping, is suggestive of a temporal link, but this is a single case with no rechallenge and no mechanism established, the weakest evidence tier. Exercise-induced anaphylaxis is typically multifactorial and cofactor-dependent, so tirzepatide's precise role is uncertain. Its value is signal-raising: clinicians seeing new exercise-associated allergic reactions in a patient recently started on tirzepatide have a reason to consider the drug as a possible cofactor. It says nothing about how common such a reaction might be, and should not shape general expectations of the drug.
Plain-language abstract
Doctors report on one patient who began having severe allergic reactions (anaphylaxis) triggered by exercise after starting tirzepatide, a medicine that acts on the GIP and GLP-1 hormone systems. When the patient stopped tirzepatide, the exercise-triggered reactions went away. The fact that symptoms stopped after halting the drug hints at a connection, but this is just one patient, the drug was not restarted to confirm, and no biological explanation was established. Exercise-triggered anaphylaxis usually involves several factors at once, so tirzepatide's exact role is unclear. The main takeaway is a heads-up for doctors: if someone develops this kind of reaction soon after starting tirzepatide, the drug is worth considering as a possible contributor. It does not tell us how often this might happen.